Physician profile
Alexander Tsynman
NPI 1518993278
$3,535.24
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $600 · 2021: $874 · 2022: $135 · 2023: $13.56 · 2024: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $126.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $860.75 | 2019-2021 | |
| Alkermes, INC. | $772.65 | 2019-2021 | |
| Lundbeck LLC | $514.59 | 2019-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $459.93 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $346.38 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $288.48 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $171.71 | 2019-2024 | Uzedy |
| Sunovion Pharmaceuticals INC. | $83.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.92 | 2019 | |
| Indivior INC. | $15.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Tsynman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.